E85.3 Secondary systemic amyloidosis

Name of the Condition

• Secondary systemic amyloidosis
• ICD-10 Code: E85.3

Summary

Secondary systemic amyloidosis is a disorder characterized by the abnormal accumulation of amyloid proteins in various organs and tissues, typically as a complication of chronic inflammatory or infectious conditions. This buildup disrupts normal organ function, potentially affecting the kidneys, liver, spleen, and other systems. The condition is distinct from hereditary forms and is linked to underlying diseases that promote amyloid deposition.

Causes

The cause of secondary systemic amyloidosis is the overproduction of certain proteins, often due to chronic inflammatory or infectious processes. These proteins misfold and deposit as amyloid, most commonly derived from serum amyloid A (SAA) protein, which is elevated in conditions like rheumatoid arthritis, tuberculosis, or osteomyelitis. The underlying disease drives the formation of amyloid deposits.

Risk Factors

• Chronic inflammatory diseases (e.g., rheumatoid arthritis, ankylosing spondylitis).
• Chronic infections (e.g., osteomyelitis, tuberculosis).
• Long-standing inflammatory bowel disease.
• Certain cancers, such as Hodgkin's lymphoma.
• Age (more common in adults with prolonged inflammatory conditions).

Symptoms

• Swelling in the ankles, legs, or abdomen due to fluid retention.
• Fatigue and unexplained weight loss.
• Kidney dysfunction, including proteinuria or reduced renal function.
• Enlarged liver or spleen (hepatosplenomegaly).
• Gastrointestinal symptoms like nausea or diarrhea.
• Shortness of breath or heart-related symptoms in severe cases.

Diagnosis

Diagnosis involves clinical evaluation, laboratory tests, and tissue biopsy. Biopsy samples are stained with Congo red to confirm amyloid deposits, often from the kidney or rectum. Laboratory tests may show elevated inflammatory markers or abnormal organ function. Imaging studies (e.g., ultrasound) can assess organ involvement, and genetic testing is not typically required unless hereditary amyloidosis is suspected.

Treatment Options

Treatment focuses on managing the underlying condition to reduce amyloid production. This may include anti-inflammatory medications, antibiotics for infections, or cancer therapy. Supportive care addresses organ dysfunction, such as diuretics for fluid retention or medications to protect kidney function. In severe cases, organ transplantation (e.g., kidney) may be considered.

Prognosis and Follow-Up

Prognosis depends on the underlying cause and extent of organ damage. Early treatment of the associated condition can slow progression, but advanced organ involvement may lead to complications. Regular monitoring of organ function (e.g., kidney, liver) and inflammatory markers is essential. Follow-up care is tailored to the underlying disease and organ-specific needs.

Complications

• Progressive kidney failure requiring dialysis or transplantation.
• Liver dysfunction or failure.
• Heart involvement leading to heart failure.
• Gastrointestinal bleeding or malabsorption.
• Increased risk of infections due to compromised organ function.

Lifestyle & Prevention

Managing the underlying inflammatory or infectious condition is key to prevention. This may involve adhering to prescribed treatments, maintaining a healthy lifestyle, and avoiding triggers that exacerbate inflammation. Regular medical check-ups to monitor organ function are recommended for those with chronic conditions at risk.

When to Seek Professional Help

Seek medical attention if you experience unexplained swelling, persistent fatigue, or symptoms of organ dysfunction (e.g., changes in urination, shortness of breath). Prompt evaluation is important for diagnosing and treating the underlying cause to prevent further amyloid deposition.

Tips for Medical Coders

Document the underlying condition driving the amyloidosis (e.g., rheumatoid arthritis, infection) as it impacts code assignment. Ensure biopsy confirmation of amyloid deposits is noted, as this supports the diagnosis. Code E85.3 is specific to secondary systemic amyloidosis and should not be used for hereditary or other amyloidosis types. Verify documentation aligns with clinical findings to support accurate coding.